Abstract
The effects of troglitazone on abnormalities of the blood coagulation-fibrinolytic system were investigated in obese NIDDM patients. The subjects were 21 NIDDM patients, 14 of whom were administered troglitazone [BMI: 26.5±3.5kg/m2 (mean±SD)] and 7 of whom received gliclazide for 12 weeks. Fasting blood samples were collected before and after administration, and the levels of plasma glucose (FPG), HbAic, insulin (IRI), C-peptide (CPR), plasminogen activator inhibitor l (PAI-1) and fibrinogerl were measured. After toglitazone administration, FPG arld HbA1c showed a significant decrease, and IRI and CPR also declined significantly. Futheremore, PAI-1 (132.4± 62.1→71.8±29.9ng/ml) and fibrinogen (297.9±55.7→250.0±41.4mg/dl) decreased significantly (p<0.01). After gliclazide administration, FPG and HbAic showed similar reductions as in the group given troglitazone. However, PAI-1 (79.9±32.2→71.0±21.7ng/ml) and fibrinogen (270.3±21.3→286.1±60.8mg/dl) showed no changes after gliclazide administration, and IRI and CPR also showed no change. In obese NIDDM patients, it appears that administration of troglitazone might improve abnormalities of the coagulation-fibrinolytic system in addition to improved glycemic control and a decrease of hyperinsulinemia.
